DP-460

DP-460 is an orally active, small molecule inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), originally developed by the biotechnology company D-Pharm. As a DPP-4 inhibitor, the compound was designed to improve glycemic control in patients with type 2 diabetes by preventing the degradation of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. Beyond its metabolic applications, DP-460 was also investigated for its potential neuroprotective effects in neurodegenerative conditions like Alzheimer's disease. The rationale for this indication was based on the ability of GLP-1 to modulate neuroinflammation, reduce amyloid-beta accumulation, and enhance neuronal survival. Clinical development of DP-460 appears to have ceased following the financial restructuring and liquidation of D-Pharm.